CapsoVision, Inc. announced that its AI Highlights feature for the CapsoCam Plus system received U.S. Food and Drug Administration clearance on September 25, 2026. The AI-assisted reading tool is designed to support physicians in reviewing small bowel capsule endoscopy studies by recognizing and marking suspected abnormal lesions, thereby reducing review time. This regulatory milestone follows the international launch of the feature earlier in the year. CapsoVision operates as a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions for gastrointestinal disease detection.
